alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit 32****Certifications Pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350)**     The undersigned, as the President and Chief Executive Officer, and Executive VicePresident and Chief Financial Officer of Exide Technologies, each certify that     (1) the accompanying Quarterly Report on Form 10-Q for the period ended September 30,2007, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of theSecurities Exchange Act of 1934, as amended; and     (2) the information contained in the periodic report fairly presents, in all materialrespects, the financial condition and results of operations of Exide Technologies at the dates andfor the periods indicated.     A signed original of this written statement required by Section 906 has been provided toExide Technologies and will be retained by Exide Technologies and furnished to the Securities andExchange Commission or its staff upon request.     The undersigned expressly disclaims any obligation to update the foregoing certificationexcept as required by law.Date: November 8, 2007                  /S/ Gordon A. Ulsh   Gordon A. Ulsh   President and Chief Executive Officer             /S/ Francis M. Corby, Jr.   Francis M. Corby, Jr.   Executive Vice President and Chief Financial Officer  
37
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

<TABLE> <S> <C>

<LEGEND>
                              THIS SCHEDULE CONTAINS SUMMARY FINANCIAL 
                              INFORMATION EXTRACTED FROM THE COMPANY'S FINANCIAL
                              STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY BY
                              REFERENCE TO SUCH FINANCIAL STATEMENTS INCLUDED
                              AS A PART OF THIS FORM 20-F
</LEGEND>
[ARTICLE]                     5
<MULTIPLIER>                                     1,000
<CURRENCY>                                           $
       
<S>                             <C>
<PERIOD-TYPE>                                     Year
<FISCAL-YEAR-END>                          Dec-31-1995
<PERIOD-START>                             Jan-01-1995
<PERIOD-END>                               Dec-31-1995
<EXCHANGE-RATE>                                      1
<CASH>                                           4,365
<SECURITIES>                                       490
<RECEIVABLES>                                    8,791
<ALLOWANCES>                                       132
<INVENTORY>                                        723
<CURRENT-ASSETS>                                14,576
<PP&E>                                             611
<DEPRECIATION>                                     179
<TOTAL-ASSETS>                                  16,907
<CURRENT-LIABILITIES>                            3,979
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         1,593
<OTHER-SE>                                      10,221
<TOTAL-LIABILITY-AND-EQUITY>                    16,907
<SALES>                                         13,824
<TOTAL-REVENUES>                                13,824
<CGS>                                            9,374
<TOTAL-COSTS>                                    2,828
<OTHER-EXPENSES>                                 (122)
<LOSS-PROVISION>                                   132
<INTEREST-EXPENSE>                                 205
<INCOME-PRETAX>                                  1,407
<INCOME-TAX>                                       221
<INCOME-CONTINUING>                              1,186
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                  1,125
<CHANGES>                                            0
<NET-INCOME>                                        61
<EPS-PRIMARY>                                     0.01
<EPS-DILUTED>                                     0.01
        

</TABLE>
#### Howard W. Sessions *v.*Arthur S. Sachs et al.

*Howard W. Sessions,*pro se, in support of the motions.

Submitted April 7

decided April 15, 1969

The motion by the plaintiff to open the hearing on the taxation of costs in the appeal from the Superior Court in Hartford County is denied.

The motion by the plaintiff for this court to review the clerk’s taxation of costs in the appeal from the Superior Court in Hartford County is denied.
#### § 56.113 Suspension or termination of IRB approval of research.

An IRB shall have authority to suspend or terminate approval of research that is not being conducted in accordance with the IRB's requirements or that has been associated with unexpected serious harm to subjects. Any suspension or termination of approval shall include a statement of the reasons for the IRB's action and shall be reported promptly to the investigator, appropriate institutional officials, and the Food and Drug Administration.
##### 



(1)
    
    The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and(2)
    
    The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations
of the Company.
 /s/ WILLIAM C. GRIFFITHS

William C. GriffithsChairman of the Board of Directors,President and Chief Executive OfficerChampion Enterprises, Inc.April 30, 2008/s/ PHYLLIS A. KNIGHT

Phyllis A. KnightExecutive Vice President, Treasurer andChief Financial OfficerChampion Enterprises, Inc.April 30, 2008
38769.

#### LEE v. THE STATE.

Carlisle, Judge.

The defendant in this case was one of the several defendants whose case was before this court under the style of *Curtis v. State,*102 Ga. App. 790 (118 S. E. 2d 264). Upon the return of the remittitur to the Superior Court of Hall County, the trial judge resentenced the defendant on each of the counts of the indictment upon which he had been found guilty by the jury, each sentence imposing *162upon him the penalty of a fine of $100 including all costs of the prosecution and carrying the further provision “that said defendant be confined in the common jail of Hall County, Georgia, until the payment of said fine of $100.” The only questions presented by this appeal are whether or not the sentences thus imposed upon this defendant are legal sentences within the meaning and intent of the decision in the cited case, and whether they are valid sentences under the provisions of *Code Ann.*§ 97-9901. It is well settled in Georgia that a judge on the conviction of one charged with a criminal offense may impose a fine upon him and provide as a means of enforcing the payment of such fine that the defendant be imprisoned until the fine is paid. Such imprisonment is no part of the punishment. *Brock v. State,*22 Ga. 98 (3); *McMeekin v. State,*48 Ga. 335 (2); *Hatchcock v. State,*88 Ga. 91, 99 (13 S. E. 959); *Green v. State,*112 Ga. 52 (2) (37 S. E. 93). The application of this rule imposes no great hardship upon the prisoner, since under the scheme of the law in this State there is a procedure by which he may be released from jail upon a proper showing to the ordinary of his insolvency and inability to pay the costs or fine, or either of them. *Code*§ 27-2804. The ruling of the ordinary on such a showing would be subject to review and any abuse of discretion on his part would constitute reversible error, thus affording the prisoner ample protection a'gainst the peril of perpetual imprisonment.

Decided February 15, 1961.

*Charles H. Edwards, H. A. Stephens, Jr.,*for plaintiff in error.

*Jeff C. Wayne, Solicitor-General, Sidney O. Smith,*contra.

*Judgment affirmed.*

*Townsend, P. J., Frankum and Jordan, JJ., concur.*
_________________________________________ 

 

 

Order Michigan Supreme Court

Lansing, Michigan 

July 31, 2006 Clifford W. Taylor,

 Chief Justice 

130430 Michael F. Cavanagh 

Elizabeth A. Weaver 

Marilyn Kelly 

PEOPLE OF THE STATE OF MICHIGAN, Maura D. Corrigan 

Robert P. Young, Jr. Plaintiff-Appellee, Stephen J. Markman,

 Justices v SC: 130430 

 COA: 255574 
 Wayne CC: 03-014112

TEJUAN LAWRENCE, 

Defendant-Appellant. 

_________________________________________/ 

On order of the Court, the application for leave to appeal the December 6, 2005 

judgment of the Court of Appeals is considered, and it is DENIED, because we are not 

persuaded that the questions presented should be reviewed by this Court. 

p0724 

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the 

foregoing is a true and complete copy of the order entered at the direction of the Court. 

July 31, 2006 

 Clerk
#### § 211.72 Filters.

Filters for liquid filtration used in the manufacture, processing, or packing of injectable drug products intended for human use shall not release fibers into such products. Fiber-releasing filters may be used when it is not possible to manufacture such products without the use of these filters. If use of a fiber-releasing filter is necessary, an additional nonfiber-releasing filter having a maximum nominal pore size rating of 0.2 micron (0.45 micron if the manufacturing conditions so dictate) shall subsequently be used to reduce the content of particles in the injectable drug product. The use of an asbestos-containing filter is prohibited.

[73 FR 51932, Sept. 8, 2008]
132 STAT. 4372 PUBLIC LAW 115–288—DEC. 6, 2018 

LEGISLATIVE HISTORY—H.R. 4913: 

CONGRESSIONAL RECORD, Vol. 164 (2018): 

Sept. 13, considered and passed House. 

Nov. 15, considered and passed Senate. 

Æ 

Public Law 115–288 

115th Congress 

An Act 

To designate the facility of the United States Postal Service located at 816 East 

Salisbury Parkway in Salisbury, Maryland, as the ‘‘Sgt. Maj. Wardell B. Turner 

Post Office Building’’. 

Be it enacted by the Senate and House of Representatives of 

the United States of America in Congress assembled, 

SECTION 1. SGT. MAJ. WARDELL B. TURNER POST OFFICE BUILDING. 

(a) DESIGNATION.—The facility of the United States Postal 

Service located at 816 East Salisbury Parkway in Salisbury, Maryland, shall be known and designated as the ‘‘Sgt. Maj. Wardell 

B. Turner Post Office Building’’. 

(b) REFERENCES.—Any reference in a law, map, regulation, 

document, paper, or other record of the United States to the facility 

referred to in subsection (a) shall be deemed to be a reference 

to the ‘‘Sgt. Maj. Wardell B. Turner Post Office Building’’. 

Approved December 6, 2018. 

Dec. 6, 2018 

[H.R. 4913] 


ralbany on LAP520R082 with PUB LAWS PDF
§ 522.1720 Phenylbutazone. ( a ) *Specifications.* ( 1 ) Each milliliter of solution contains 100 milligrams (mg) of phenylbutazone.
( 2 ) Each milliliter of solution contains 200 mg of phenylbutazone.
( b ) *Sponsors.* See sponsor numbers in § 510.600(c) of this chapter for use as in paragraph (c) of this section: ( 1 ) No. 054771 for use of product described in paragraph (a)(1) as in paragraph (c) of this section.
( 2 ) Nos. 000061, 054771, 058198, and 061133 for use of product described in paragraph (a)(2) of this section as in paragraph (c) of this section.
( 3 ) Nos. 058005 and 069043 for use of product described in paragraph (a)(2) as in paragraph (c)(2) of this section.
( c ) *Conditions of use* — ( 1 ) *Dogs* — ( i ) *Amount.* Administer by intravenous injection 10 mg per pound of body weight daily in three divided doses, not to exceed 800 mg daily regardless of weight. Limit intravenous administration to 2 successive days. Oral medication may follow.
( ii ) *Indications for use.* It is used for the relief of inflammatory conditions associated with the musculoskeletal system.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Horses* — ( i ) *Amount.* Administer by intravenous injection 1 to 2 grams (g) per 1,000 pounds of body weight daily in three divided doses, not to exceed 4 g daily. Limit intravenous administration to not more than 5 successive days.
( ii ) *Indications for use.* For the relief of inflammatory conditions associated with the musculoskeletal system.
( iii ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16193, Mar. 25, 2014, as amended at 83 FR 48946, Sept. 28, 2018; 84 FR 8974, Mar. 13, 2019; 86 FR 14820, Mar. 19, 2021]
Editorial Note on Part 316
Editorial Note: Nomenclature changes to part 316 appear at 69 FR 13717, Mar. 24, 2004.

§ 316.34 FDA recognition of exclusive approval. ( a ) FDA will send the sponsor (or, the permanent-resident agent, if applicable) timely written notice recognizing exclusive approval once the marketing application for a designated orphan-drug product has been approved, if the same drug has not already been approved for the same use or indication. The written notice will inform the sponsor of the requirements for maintaining orphan-drug exclusive approval for the full 7-year term of exclusive approval.
( b ) When a marketing application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) for a designated orphan drug that qualifies for exclusive approval, FDA will publish in its publication entitled “Approved Drug Products With Therapeutic Equivalence Evaluations” information identifying the sponsor, the drug, and the date of termination of the orphan-drug exclusive approval. A subscription to this publication and its monthly cumulative supplements is available from the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325, and is also available online at *http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm .*
( c ) If a drug is otherwise the same drug as a previously approved drug for the same use or indication, FDA will not recognize orphan-drug exclusive approval if the sponsor fails to demonstrate upon approval that the drug is clinically superior to the previously approved drug.
[78 FR 35135, June 12, 2013]
A. 

''''^>^RT]€NTOF 

SERVED JANUARY 21, 2011 

• ^ , 

i I 

U.S. DEPARTMENT OF TRANSPORTATION 

OFFICE OF HEARINGS 

WASHINGTON, DC 

IN THE MATTER OF 

SAMUEL JOSEPH LATHAM 

FAA DOCKET No. CP10WP0009 

(Civil Penalty Case) 

DMS No. FAA-2010-0624 

ORDER DENYING RESPONDENT'S 

MOTION FOR PROTECTIVE ORDER 

Samuel Joseph Latham ("Respondent" or "Mr. Latham") filed a motion on 

December 6, 2010 for a protective order under section 13.220 of the Rules of Practice in 

FAA Civil Penalty Actions ("Rules of Practice") 14 C.F.R. §13.220. Complainant 

Federal Aviation Administration ("Complainant") has answered in opposition. 

To prevail on his motion, section 13.220(h) of the Rules of Practice requires Mr. 

Latham to show that a protective order is necessary to protect him "fi-om annoyance, 

embarrassment, oppression, or undue burden or expense." He has not made this showing. 

The motion is unsupported; it contains no more than a bare assertion. Under these 

circumstances, the motion is DENIED. 

Mr. Latham shall fulfill the terms of the Order Granting Complainant's Motion 

served November 10, 2010 ("the Order") by January 28, 2010 (mailing date), or risk 

sanctions as detailed in Paragraph 3 of the Order. 
1 - . ...:,»:•; llffl'W ^^g|| M 

SO ORDERED 

Attachment - Service List tive Law Judge 

^'-3^l.Pi 

? *»- j 

"i'/' i 

k4;£':,-Aikji4^.?it^--.>.v 
FAA Docket No. CP10WP0009 

(Civil Penalty Action) 

SERVICE LIST 

ORIGINAL & ONE COPY 

Federal Aviation Administration 

800 Independence Avenue, S.W. 

Washington, DC 20591 

Attention: Hearing Docket Clerk, AGC-430 

Wilbur Wright Building - Suite 2W1000' 

ONE COPY 

Samuel Joseph Latham, Respondent 

33690 Almond St. 

Wildomar, CA 92595 

TEL: 951-392-4897 

Lierre Green, Complainant's Counsel 

Office of the Regional Counsel 

Western-Pacific Region, AWP-7 

Federal Aviation Administration 

P.O. Box 92007 

Los Angeles, CA 90009-2007 

TEL: 310-725-7117 

FAX: 310-725-6816 

The Honorable Richard C. Goodwin, Administrative Law Judge 

Office of Hearings, M-20 

U.S. Department of Transportation 

1200 New Jersey Avenue, S.E. 

East Building Ground Floor, Room E12-3 20 

Washington, DC 20590 

TEL: Attorney-Advisor 202-366-2139 

Legal Assistant 202-366-5121 

FAX: 202-366-7536 

' Service was by U.S. Mail. For service in person or by expedited courier, use the following address: 

Hearing Docket, Federal Aviation Administration, 600 Independence Avenue, S.W., Wilbur Wright Building - Room 

2014, Washington, DC 20591, Attention: Hearing Docket Clerk, AGC-430.
§ 58.185 Reporting of nonclinical laboratory study results. ( a ) A final report shall be prepared for each nonclinical laboratory study and shall include, but not necessarily be limited to, the following: ( 1 ) Name and address of the facility performing the study and the dates on which the study was initiated and completed.
( 2 ) Objectives and procedures stated in the approved protocol, including any changes in the original protocol.
( 3 ) Statistical methods employed for analyzing the data.
( 4 ) The test and control articles identified by name, chemical abstracts number or code number, strength, purity, and composition or other appropriate characteristics.
( 5 ) Stability of the test and control articles under the conditions of administration.
( 6 ) A description of the methods used.
( 7 ) A description of the test system used. Where applicable, the final report shall include the number of animals used, sex, body weight range, source of supply, species, strain and substrain, age, and procedure used for identification.
( 8 ) A description of the dosage, dosage regimen, route of administration, and duration.
( 9 ) A description of all circumstances that may have affected the quality or integrity of the data.
( 10 ) The name of the study director, the names of other scientists or professionals, and the names of all supervisory personnel, involved in the study.
( 11 ) A description of the transformations, calculations, or operations performed on the data, a summary and analysis of the data, and a statement of the conclusions drawn from the analysis.
( 12 ) The signed and dated reports of each of the individual scientists or other professionals involved in the study.
( 13 ) The locations where all specimens, raw data, and the final report are to be stored.
( 14 ) The statement prepared and signed by the quality assurance unit as described in § 58.35(b)(7).
( b ) The final report shall be signed and dated by the study director.
( c ) Corrections or additions to a final report shall be in the form of an amendment by the study director. The amendment shall clearly identify that part of the final report that is being added to or corrected and the reasons for the correction or addition, and shall be signed and dated by the person responsible.
[43 FR 60013, Dec. 22, 1978, as amended at 52 FR 33781, Sept. 4, 1987]
### D ISTRICT 

### C OURT 

### O F 

### A PPEAL 

### O F 

### T HE 

### S TATE 

### O F 

### F LORIDA

F OURTH D ISTRICT

FREDERICK FOSTER

, Appellant,

v.

STATE OF FLORIDA

, Appellee

.

No. 4D 17

- 2871

[ December 7, 2017 ]

Appeal of order denying rule 3.800 motion from the Circuit Court for

the Fifteenth Judicial Circuit, Palm Beach County ; John S. Kastrenakes

, Judge; L.T. Case No s

. 50 2002 CF 005030 and 50 2002 CF 000197

.

Frederick Foster, Okaloosa, pro se.

No appearance required for appellee.

P ER C URIAM

.

Affirmed.

G ROSS

, T AYLOR and M AY

, JJ., concur.

* * *

Not final until disposition of timely filed motion for rehearing.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM FINANCIAL
STATEMENTS INCLUDED IN TCI PACIFIC COMMUNICATIONS, INC.'S QUARTERLY REPORT ON
FORM 10-Q FOR THE PERIOD ENDED MARCH 31, 1997 AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                                   14,703
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                         406,055
<DEPRECIATION>                                  23,667
<TOTAL-ASSETS>                               3,410,225
<CURRENT-LIABILITIES>                                0
<BONDS>                                      1,042,011
<PREFERRED-MANDATORY>                          629,551
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                     628,078
<TOTAL-LIABILITY-AND-EQUITY>                 3,410,225
<SALES>                                              0
<TOTAL-REVENUES>                               124,952
<CGS>                                                0
<TOTAL-COSTS>                                   42,520
<OTHER-EXPENSES>                                31,662
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              25,307
<INCOME-PRETAX>                                (1,546)
<INCOME-TAX>                                      (71)
<INCOME-CONTINUING>                            (1,475)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (1,475)
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Agriculture

###### Forest Service

# AGENCY:

Forest Service, USDA.

# ACTION:

                        Cancellation of Notice of intent to prepare an Environmental Impact Statement published in the                         **Federal Register**                         on April 3, 2000 (page 17482).                    

# SUMMARY:

The Department of Agriculture, Forest Service is issuing this notice to advise the public that we are canceling the Notice of Intent (NOI) to prepare Kosciusko Island Timber Sale Environmental Impact Statement (EIS) to assess and disclose the environmental effects of timber harvest and road building to provide timber for the Tongass National Forest Timber Sale Program.

# FOR FURTHER INFORMATION CONTACT:

Frank Roberts, Zone Planner, Thorne Bay Ranger District, Tongass National Forest, P.O. Box 19001, Thorne Bay, AK 99919, telephone: 907-828-3250.

# SUPPLEMENTARY INFORMATION:

The 47,007-acre Kosciusko Project Area is located approximately 48 air miles northwest of Thome Bay, Alaska. A Draft Environmental Impact Statement for this project was published in 1993.

Dated: February 16, 2010.

Forrest Cole,

Forest Supervisor, Tongass National Forest.

[FR Doc. 2010-3517 Filed 2-23-10; 8:45 am]

BILLING CODE 3410-GM-M